Published in the journal ESMO Gastrointestinal Oncology, results of a VHIO-led retrospective and multicenter study show that 3.4% of pancreatic…
Results from an international Phase IIa study point to the promise of adding bispecific HER2-targeted antibody zanidatamab to the combination…
Published as a Resource article in the open access journal Cell Reports*, results from an international study co-led by investigators…
Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint…
In her latest On target column, published by ESMO’s Daily Reporter, VHIO’s Elena Garralda reflects on the myriad research advances presented at last month’s…
The 1st VHIO-BBVA Foundation International Symposium on Cell-based Therapies in Oncology , organised by Dr. Alena Gros, head of the…
Vall d’Hebron Barcelona Hospital Campus has celebrated its first PhD Day, a whole day of scientific activities created for and…
Biliary tract cancer (BTC) poses a distinctive challenge in oncology, mainly due to diagnosis at late-stage and limited effective systemic…
Clarivate, a global leader in connecting people and organizations to intelligence to transform the world, has revealed its list of…
Approximately 10% of patients with metastatic castration-resistant prostate cancer have alterations in the BRCA1 or BRCA2 genes which are associated…
Laboratory tests with mice reveal ‘exciting’ new strategy that could transform triple-negative breast cancer into a manageable disease Researchers at…
The biotech company Peptomyc SL announced today that it has been awarded €5 million blended financing from the Horizon Europe,…
